Indivior Pharmaceuticals (INDV) EPS (Basic) (2024 - 2026)

Indivior Pharmaceuticals' EPS (Basic) history runs 3 years deep, the most recent figure standing at $0.72 for Q1 2026.

• On a quarterly basis, EPS (Basic) rose 85.42% year-over-year to $0.72 in Q1 2026; TTM through Mar 2026 was $2.02, a 3685.71% increase from a year earlier, with the FY2025 full-year figure at $1.68, up 3068.0% from the prior year.
• EPS (Basic) slipped to $0.72 in Q1 2026 per INDV's latest filing, from $0.82 in the prior quarter.
• Across five years, EPS (Basic) topped out at $0.82 in Q4 2025 and bottomed at -$0.73 in Q2 2024.
• The 3-year median for EPS (Basic) is $0.34 (2025), against an average of $0.27.
• Biggest YoY gain for EPS (Basic) was 412.91% in 2025; the steepest drop was 15.09% in 2025.
• Year by year, EPS (Basic) stood at $0.16 in 2024, then surged by 412.91% to $0.82 in 2025, then slipped by 12.04% to $0.72 in 2026.
• Per Business Quant, the three latest INDV EPS (Basic) figures stand at $0.72 (Q1 2026), $0.82 (Q4 2025), and $0.34 (Q3 2025).